Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines - Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer.

These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease.

Written by:
Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA Are you the author?
From 1Roswell Park Cancer Institute; 2Duke Cancer Institute; 3The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 4St. Jude Children's Research Hospital/University of Tennessee Cancer Institute; 5University of Alabama at Birmingham Comprehensive Cancer Center; 6Dana-Farber/Brigham and Women's Cancer Center; 7Memorial Sloan-Kettering Cancer Center; 8UNMC Eppley Cancer Center at The Nebraska Medical Center; 9Prostate Health Education Network, Inc.; 10University of Washington/Seattle Cancer Care Alliance; 11Fox Chase Cancer Center; 12City of Hope Comprehensive Cancer Center; 13Massachusetts General Hospital Cancer Center; 14Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 15Vanderbilt-Ingram Cancer Center; 16University of Michigan Comprehensive Cancer Center; 17Moffitt Cancer Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The University of Texas MD Anderson Cancer Center; 20University of California, San Francisco; 21Stanford Cancer Institute; 22Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 23Huntsman Cancer Institute at the University of Utah; 24The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and 25National Comprehensive Cancer Network.

Reference: J Natl Compr Canc Netw. 2012 Sep 1;10(9):1081-1087.


PubMed Abstract
PMID: 22956807